Why did you decide to participate in the Biomapas Academy?
The first time I heard about Biomapas Academy was from a friend who was already working in the pharmacy field. She sent me an advertisement for Biomapas Academy, which highly intrigued me. As I was in my last year of life science master studies, I wanted to discover my potential career possibilities and learn more about clinical trials. Therefore, without long thinking, I filled in the application form. I was very happy to be selected from quite many applicants and be invited to attend Biomapas Academy.
How was your experience during the three months?
We had four months of weekly lectures on different topics. They were related to the organization of clinical trials, regulatory affairs and pharmacovigilance of various medical products. Biomapas experts who resented the lectures even shared their personal experience and actual practical examples with us. We have been able to get acquainted with Biomapas company and its work specifics. Here we could expand our knowledge of the pharmaceutical industry.
How do you feel after graduating from the Academy?
I feel thrilled for taking a chance to participate in this unique project. After graduating from all the courses and tasks, I was absolutely honoured to be selected as the best student of Biomapas Academy 2020 and receive a scholarship. However, I mostly appreciate the valuable knowledge and experience I believe will be helpful for my future career. I think Biomapas Academy definitely contributes to the education of young professionals and is very useful, especially for those who want to get to know their professional opportunities better.
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
MENA PV Landscape – Key Updates & Inspection Trends
Timely insights on the evolving Pharmacovigilance landscape in the MENA region.
Navigating Pharmacovigilance Requirements in LATAM
Insights into the evolving Pharmacovigilance landscape across the LATAM region.
Centralized Pharmacovigilance: Ensuring Compliance and Efficiency Across Global Markets
This article explores the benefits of centralized pharmacovigilance outsourcing and the single-provider model.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
Discover insights on diversity in clinical trials, regulatory compliance to inclusion, the European approach, and trial design innovations.
Biomapas Welcomes David Passov as Chief Executive Officer
Press Release Biomapas Welcomes David Passov as Chief Executive OfficerWe are pleased to announce the appointment of David Passov, MBA, as our new Chief Executive Officer, effective 21st February 2025. David Passov brings extensive leadership experience in life...
How functional service provision (FSP) helps biotech companies streamline clinical trial operations
In recent years, biotech companies face pressure to optimize clinical trial operations while managing costs, ensuring regulatory compliance, and maintaining flexibility. This is where Functional Service Provision (FSP) comes in. FSP offeres a scalable, flexible...
Functional Service Provision As Smarter Approach to Clinical Trial Execution
For biotech and pharmaceutical companies, the challenge isn’t just innovation but execution too. Functional Service Provision (FSP) enables organizations to optimize clinical trials without the bottlenecks of traditional outsourcing. As competition intensifies and...
Pharmacovigilance Auditing: Understanding the Process and Maximizing Its Benefits
Discover how pharmacovigilance audits go beyond compliance to uncover hidden risks, drive improvement, and ensure every patient gets the safest treatment possible.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
In light of recent developments, we must recognise that diversity in clinical trials is not just a buzzword anymore, it is a key priority. Yet, with varying perspectives from regulatory agencies worldwide, and an industry still unaligned on the best approaches, there...
All you need to know about the FDA’s Draft Guidance on Diversity Action Plans
The U.S. Food and Drug Administration’s (FDA) draft guidance on Diversity Action Plans (DAPs) is a significant step towards addressing the underrepresentation of diverse populations in clinical research. Released in June 2024, this guidance aligns with broader efforts...
